Diffuse Large B-cell Lymphoma (DLBCL) Market to Surpass USD 16.5 Billion by 2034

The DLBCL market across the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan was valued at ~ USD 5 billion in 2024 and is projected to exceed USD 16.5 billion by 2034, driven by the growing adoption of advanced immunotherapies, label expansions, and the introduction of novel pipeline assets. The United States dominated the market in 2024, accounting for approximately USD 3.1 billion, driven by a high patient pool and robust therapeutic adoption.

Despite its aggressive nature, DLBCL remains potentially curable, with incidence rising notably among individuals over 60 years. RITUXAN (rituximab) continues to be the therapeutic backbone in both first-line and relapsed settings due to its proven efficacy as a CD20-targeting monoclonal antibody. While 60% of patients achieve remission with R-CHOP frontline therapy, the remaining 40% relapse or show resistance, necessitating salvage regimens like R-GemOx, R-ICE, or R-DHAP, though none have established clear superiority.

Advancements in cellular and bispecific antibody therapies are redefining the treatment landscape. CAR T-cell therapies such as YESCARTA, BREYANZI, and KYMRIAH have transformed outcomes in relapsed/refractory DLBCL, with ongoing trials exploring their potential first-line use. Meanwhile, off-the-shelf bispecific antibodies that target CD20 and CD3 are demonstrating strong efficacy by engaging both tumor and immune cells simultaneously.

A key upcoming innovation includes Cemacabtagene ansegedleucel (Allogene Therapeutics), an allogeneic CD19 CAR-T therapy in Phase II evaluation for first-line consolidation, potentially marking a breakthrough in treatment accessibility. Additionally, the anticipated launch of novel assets such as Zilovertamab vedotin (Merck), Zamtocabtagene autoleucel (Miltenyi Biomedicine), Rapcabtagene autoleucel (Novartis), and Golcadomide (BMS) is expected to further accelerate market expansion. Supported by a rising disease burden and continued innovation, the DLBCL market is poised for strong and sustained growth across the 7MM through 2034.

DelveInsight’s “Diffuse Large B-cell Lymphoma Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Diffuse Large B-cell Lymphoma, historical and forecasted epidemiology as well as the Diffuse Large B-cell Lymphoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Diffuse Large B-cell Lymphoma Market Overview and Outlook

Diffuse Large B-cell Lymphoma (DLBCL) remains the most common subtype of non-Hodgkin lymphoma (NHL), representing nearly 30% of global lymphoma cases. While 60% of patients achieve remission with frontline R-CHOP therapy, the remaining 40% face relapse or refractory disease—creating an urgent need for next-generation therapies.

The Diffuse Large B-cell Lymphoma market is undergoing a paradigm shift, fueled by CAR-T therapies, bispecific antibodies, monoclonal antibodies, and small-molecule inhibitors. Approved therapies such as YESCARTA, BREYANZI, KYMRIAH, EPKINLY, COLUMVI, KEYTRUDA, POLIVY, and MONJUVI continue to dominate treatment regimens, while emerging drugs like Zilovertamab vedotin (Merck), Zamtocabtagene autoleucel (Miltenyi Biomedicine), Cemacabtagene ansegedleucel (Allogene Therapeutics), Rapcabtagene autoleucel (Novartis), and Golcadomide (BMS) are expected to reshape the therapeutic landscape by 2034.

Key Diffuse Large B-cell Lymphoma Market Growth Drivers

1. Rising Disease Incidence and Aging Population
   Global DLBCL incidence exceeds 150,000 cases annually, driven by an aging population, with incident cases in the 7MM projected to reach ~87,000 by 2034.
2. Expansion of Targeted Therapies and Immunotherapies
   The growing clinical adoption of CAR-T and bispecific antibodies in earlier lines of therapy—along with label extensions for existing agents—will significantly expand market penetration.
3. Robust R&D Pipeline and Clinical Advancements
   Over 30 global biopharma companies, including Roche (Genentech), BMS, Biogen, Novartis, AstraZeneca, Pfizer, BeiGene, and Gilead Sciences, are advancing clinical programs in CAR-T, bispecifics, and novel immunomodulators, enhancing the innovation ecosystem.
4. Enhanced Diagnostic Precision and Early Detection
   The integration of PET-CT, molecular profiling, and next-generation sequencing (NGS) has improved early detection and treatment stratification by nearly 20%, enabling more effective personalized interventions.

DLBCL Epidemiology

In 2024, the total incident cases of Diffuse Large B-cell Lymphoma (DLBCL) across the seven major markets (7MM) were estimated at around 77,000, a figure expected to rise by 2034 due to an aging population and improved diagnostic capabilities. Within the EU4 and the UK, Germany reported the highest number of new cases (~7,700), followed by France, while Spain recorded the lowest incidence. In Japan, DLBCL incidence was notably higher in males compared to females.

Age-wise, the 75–84-year demographic represented the largest proportion of new DLBCL cases in the EU4 and UK, followed by those aged 65–74 years and over 84 years, with the under-20 group showing minimal incidence. Clinically, around 30–40% of patients are diagnosed at localized Stage I or II, whereas the remainder present with advanced-stage disease. Furthermore, nearly 50% of patients with relapsed or refractory (R/R) DLBCL are ineligible for transplantation due to age or comorbidities.

Among the disease subtypes, DLBCL, Not Otherwise Specified (NOS) constitutes the majority of cases. In the United States, approximately 27,000 DLBCL, NOS cases were identified in 2024, projected to reach 33,000 by 2034.

Diffuse Large B-cell Lymphoma Epidemiology Segmentation

• Total DLBCL incident cases
• Gender-specific DLBCL cases
• Age-specific DLBCL cases
• Type-specific DLBCL cases
• Stage-specific DLBCL incident cases
• DLBCL Treated cases

Diffuse Large B-cell Lymphoma Market Dynamics and Treatment Landscape

The R-CHOP regimen remains the frontline standard for newly diagnosed patients; however, integration with agents like lenalidomide and bortezomib is expanding therapeutic reach in high-risk populations.
For relapsed/refractory DLBCL, CAR-T therapies (YESCARTA, BREYANZI, KYMRIAH) have become key pillars, demonstrating superior efficacy in early-relapsed cases.
The third-line segment has seen rapid uptake of bispecific antibodies, notably EPKINLY (epcoritamab) and COLUMVI (glofitamab), approved across the U.S., Europe, and Japan.

Emerging assets like Cemacabtagene ansegedleucel, an allogeneic “off-the-shelf” CAR-T therapy, are being evaluated in first-line consolidation settings—potentially marking a breakthrough in accessibility and treatment timelines.

Diffuse Large B-cell Lymphoma Competitive Landscape

The DLBCL pipeline includes promising candidates such as:

• Zamtocabtagene Autoleucel (Miltenyi Biomedicine) – dual-target CAR-T (CD19/CD20) under EU PRIME designation.
• AZD0486 (AstraZeneca) – bispecific T-cell engager with improved cytokine safety profile.
• Maveropepimut-S (ImmunoVaccine Technologies) – therapeutic vaccine advancing in Phase II trials.
• IMPT-314 (Lyell/ImmPACT Bio) – next-generation CAR-T with enhanced persistence.

Recent Developments in Diffuse Large B-cell Lymphoma Market include:

• June 2025 – Genmab announced promising results for epcoritamab + R-ICE combination in relapsed/refractory DLBCL.
• April 2025 – European Commission approved COLUMVI + gemcitabine/oxaliplatin for transplant-ineligible patients.
• March 2025 – Imugene received FDA Fast Track Designation for allogeneic CAR-T candidate azercabtagene zapreleucel.

Scope of Diffuse Large B-cell Lymphoma Market

• Study Period: 2020–2034
• Market Coverage: 7MM [The United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
• Diffuse Large B-cell Lymphoma Market CAGR in the 7MM (2020-2034): ~13%
• Diffuse Large B-cell Lymphoma Market Size in 2025 in the 7MM: USD 5,286 million
• Key Diffuse Large B-cell Lymphoma Companies: BMS, Roche (Genentech), Biogen, Nektar Therapeutics, Merck, Allogene Therapeutics, Miltenyi Biomedicine, AstraZeneca, BioVaxys, ImmunoVaccine Technologies, Cellectar Biosciences, Galapagos, Novartis, Lyell, ImmPACT Bio, Pfizer, Kartos Therapeutics, 2seventy bio, Regeneron Pharmaceuticals, BeiGene, Ranok Therapeutics, Constellation Pharmaceuticals, Genmab, IDP Discovery Pharma S.L., Immunitas Therapeutics, Monte Rosa Therapeutics, SymBio Pharmaceuticals, Eagle Pharma, AVM Biotechnology, Autolus Therapeutics, Kymera Therapeutics, Otsuka Pharmaceutical, Caribou Biosciences, Adicet Bio, Gilead Sciences, Xynomic Pharmaceuticals, Amgen, and others
• Key Diffuse Large B-cell Lymphoma Therapies: LUNSUMIO (mosunetuzumab), NKTR-255 + CD19 CAR-T cell therapy, Zilovertamab vedotin, Cemacabtagene ansegedleucel, Zamtocabtagene autoleucel (MB-CART2019.1), AZD0486, CALQUENCE (acalabrutinib), Maveropepimut-S, Iopofosine I 131 (CLR 131), GLPG5101, Rapcabtagene Autoleucel (YTB323), IMPT-314, Maplirpacept (PF-07901801), Navtemadlin (KRT-232), bbT369, BGB-16673, RNK05047, Tulmimetostat (CPI-0209), GEN3014, IDP-121, IMT-009, MRT-2359, Brincidofovir (SyB V-1901), AVM0703, Obecabtagene Autoleucel (Obe-cel), AUTO3, KT-413, OPB-111077, CB-010, ADI-001, KITE-197, KITE-363, KITE-753, KITE-197, Abexinostat, KYPROLIS (Carfilzomib), and others
• Diffuse Large B-cell Lymphoma Future Outlook: The DLBCL market is forecast to expand at a CAGR of nearly 13% (2020–2034) across the 7MM, reflecting transformative shifts toward personalized, cell-based, and immune-mediated therapies. The upcoming decade will witness broader first-line CAR-T applications, multi-target immunotherapies, and synergistic combination regimens, positioning DLBCL as one of the most rapidly evolving hematologic oncology segments.

About DelveInsight

DelveInsight is a leading healthcare consulting and market research firm specializing in pharmaceutical and biotech intelligence, offering end-to-end solutions in market forecasting, pipeline analysis, competitive intelligence, and strategic consulting. With extensive expertise across oncology, immunology, and rare diseases, DelveInsight empowers clients to make data-driven, growth-oriented decisions.